Buscar en
Seminarios de la Fundación Española de Reumatología
Toda la web
Inicio Seminarios de la Fundación Española de Reumatología Tratamiento del síndrome antifosfolipídico en el embarazo
Información de la revista
Vol. 7. Núm. 2.
Páginas 59-69 (Junio 2006)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 7. Núm. 2.
Páginas 59-69 (Junio 2006)
DOI: 10.1016/S1577-3566(06)75081-3
Acceso a texto completo
Tratamiento del síndrome antifosfolipídico en el embarazo
Visitas
...
Irama Villar, Guillermo Ruiz-Irastorza
Servicio de Medicina Interna. Hospital de Cruces. Universidad del País Vasco. Barakaldo. Bizkaia. España
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Resumen

El síndrome antifosfolipídico (SAF) es una reconocida causa de complicaciones en el embarazo, como la trombosis materna, la preeclampsia y la mortalidad embriofetal. El tratamiento de las mujeres embarazadas con SAF exige un abordaje multidisciplinario médico-obstétrico, así como intervención terapéutica basada en la combinación de ácido acetilsalicílico y heparina. Si bien las pautas concretas son discutibles por las importantes limitaciones de los estudios existentes, hay cierto grado de consenso en la recomendación del tratamiento combinado en mujeres con trombosis y/o muertes fetales previas. Las pacientes con historia exclusiva de abortos tempranos son el grupo en el que más se debate sobre la actitud a seguir, si bien el ácido acetilsalicílico en monoterapia sigue siendo una opción. En cualquiera de las situaciones, es fundamental una correcta tromboprofilaxis periparto en todas las mujeres con anticuerpos antifosfolipídicos.

Palabras clave:
Síndrome antifosfolipídico
Gestación
Aborto
Abstract

The antiphospholipid syndrome (APS) is a well known cause of pregnancy complications, including maternal thrombosis and preeclampsia as well as embryofetal losses. A multidisciplinary, medical-obstetric approach is of great importance in the clinical management of pregnant women with APS. Therapeutic interventions are based on the combination acilsalycilic acid-heparin. Although the specific combinations in different situations are still a matter of debate – due to important limitations of the available studies–, combined treatment with both drugs is usually recommended in women with previous thrombosis and/or fetal death. Aspirin alone is still a reasonable option for women with early losses, although controversy is particularly important in this group. In any situation, an adequate thromboprophylaxis in the peripartum period is warranted.

Key words:
Antiphospholipid Syndrome
Pregnancy
Miscarriage
El Texto completo está disponible en PDF
Bibliografía
[1.]
D.W. Branch, M.A. Khamashta.
Antiphospholipid syndrome: obstetric diagnosis, management and controversies.
Obstet Gynecol, 101 (2003), pp. 1333-1344
[2.]
A.E. Gharavi, S.S. Pierangeli, R.A. Levy, et al.
Mechanisms of pregnancy loss in antiphospholipid syndrome.
Clin Obstet Gynecol, 44 (2001), pp. 11-19
[3.]
G. Girardi, P. Redecha, J.E. Salmon.
Heparin prevents antiphospholid antibody-induced fetal loss by inhibiting complement activation.
Nature Med, 10 (2004), pp. 1222-1226
[4.]
S.S. Pierangeli, M. Vega-Ostertag, X. Liu, et al.
An anti C5 monoclonal antibody reverses antiphospholipid-induced thrombosis [abstract].
Arthritis Rheum, 50 (2004), pp. S639-S640
[5.]
G. Ruiz-Irastorza, M.A. Khamashta.
Lupus eritematoso sistémico, síndrome antifosfolípido y embarazo.
Semin Fund Esp Reumatol, (2000), pp. 1332-1341
[6.]
M.R. Toglia, J.G. Weg.
Venous thromboembolism during pregnancy.
N Engl J Med, 355 (1996), pp. 108-114
[7.]
T. Godfrey, D. D’Cruz.
Antiphospholipid syndrome: general features.
Hughes’ syndrome, pp. 8-19
[8.]
R. Cervera, J.C. Piette, J. Font, et al.
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.
Arthritis Rheum, 46 (2002), pp. 1019-1027
[9.]
M.J. Cuadrado, L.L.F. Mendoza, M.A. Khamashta, et al.
Maternal and fetal outcome in antiphospholipid syndrome pregnancies with a history of previous cerebral ischemia.
Arthritis Rheum, 42 (1999), pp. S265
[10.]
D.W. Branch, R.M. Silver, J.L. Blackwell, et al.
Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the UTA experience.
Obstet Gynecol, 80 (1992), pp. 614-620
[11.]
F. Lima, M.A. Khamashta, N.M. Buchanan, et al.
A study of sixty pregnancies in patients with the antiphospholipid syndrome.
Clin Exp Rheumatol, 14 (1996), pp. 131-136
[12.]
R. Pauzner, M. Dulitzki, P. Langevitz, et al.
Low molecular weight heparin and warfarin the treatment of patients with antiphospholipid syndrome during pregnancy.
Thromb Haemost, 86 (2001), pp. 1379-1384
[13.]
M.D. Lockshin, M.L. Druzin, T. Qamar.
Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody.
Am J Obstet Gynecol, 160 (1989), pp. 439-443
[14.]
D.L.T. Huong, B. Wechsler, O. Bletry, et al.
A study of 75 pregnanciesin patients with antiphospholipid syndrome.
J Rheumatol, 28 (2001), pp. 2025-2030
[15.]
S. Stone, M.A. Khamashta, L. Poston.
Placentation, antiphospholipid syndrome and pregnancy outcome.
Lupus, 10 (2001), pp. 67-74
[16.]
D.W. Branch, T.F. Porter, L. Rittenhouse, et al.
Antiphospholipid antibodies in women at risk for pre-eclampsia.
Am J Obstet Gynecol, 184 (2001), pp. 825-832
[17.]
K. Duckitt, D. Harrington.
Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies.
[18.]
G.A. Dekker, J.I. De Vries, P.M. Doelitzsch, et al.
Underlying disorders associated with severe early-onset pre-eclampsia.
Am J Obstet Gynecol, 173 (1995), pp. 1042-1048
[19.]
M. Petri.
Hopkins lupus pregnancy center: 1987 to 1996.
Rheum Dis Clin North Am, 23 (1997), pp. 1-13
[20.]
M.H. Orstein, J.H. Rand.
An association between refractory HELLP syndrome an antiphospholipid antibodies during pregnancy: a report of 2 cases.
J Rheumatol, 21 (1994), pp. 1360-1364
[21.]
N. Galie, A. Manes, K.V. Farahani, et al.
Pulmonary arterial hypertension associated to connective tissue diseases.
Lupus, 14 (2005), pp. 713-717
[22.]
M. Lupton, E. Oteng-Ntim, G. Ayida, et al.
Cardiac disease in pregnancy.
Curr Opin Obstet Gynecol, 14 (2002), pp. 137-143
[23.]
M. Humbert, O. Sitbon, G. Simonneau.
Treatment of pulmonary arterial hypertension.
N Engl J Med, 351 (2004), pp. 1425-1436
[24.]
R.H. Derksen, M.A. Khamashta, D.W. Branch.
Management of the obstetric antiphospholipid syndrome.
Arthritis Rheum, 50 (2004), pp. 1028-1039
[25.]
G. Ruiz-Irastorza, M.A. Khamashta, C. Nelson-Piercy, et al.
Effects of lupus and antiphospholipid syndrome on pregnancy.
Yearbook of Obstetrics and Gynaecology, 10 (2002), pp. 105-119
[26.]
S. Loizou, M.A. Byron, H.J. Englert, et al.
Association of quantitative anticardiolipin antibody levels with fetal loss and time of loss in systemic lupus erythematosus.
Q J Med, 68 (1988), pp. 525-531
[27.]
B.T. Oshiro, R.M. Silver, J.R. Scott, et al.
Antiphospholipid antibodies and fetal death.
Obstet Gynecol, 87 (1996), pp. 489-493
[28.]
R.C.W. Wong.
Consensus guidelines for anticardiolipin antibody testing.
Thromb Res, 114 (2004), pp. 559-571
[29.]
R.H.W.M. Derksen, P.G. De Groot.
Tests for lupus anticoagulante revisited.
Throm Res, 114 (2004), pp. 521-526
[30.]
M.D. Lockshin.
Which patients with antiphospholipid antibody should be treated and how?.
Rheum Dis Clin North Am, 19 (1993), pp. 235-247
[31.]
S. Welsch, D.W. Branch.
Antiphospholipid syndrome in pregnancy: obstetric concerns and treatment.
Rheum Dis Clin North Am, 23 (1997), pp. 71-84
[32.]
R.M. Silver, T.F. Porter, I. Van Leeuween, et al.
Anticardiolipin antibodies: clinical consequences of “low titers”.
Obstet Gynecol, 87 (1996), pp. 494-500
[33.]
A. Lynch, R. Silver, W. Emlen, et al.
Antiphospholipid antibodies in healthy pregnant women.
Rheum Dis Clin North Am, 23 (1997), pp. 55-70
[34.]
M. Petri.
Diagnosis of antiphospholipid antibodies.
Rheum Dis Clin North Am, 20 (1994), pp. 443-469
[35.]
R.H.W.M. Derksen, H.J. Out, L. Blokzijl, et al.
Detection of the lupus anticoagulant in pregnancy.
Clin Exp Rheumatol, 10 (1992), pp. 323-324
[36.]
D.W. Branch, J.R. Scott, N.K. Kochenour, et al.
Obstetric complications associated with the lupus anticoagulant.
N Engl J Med, 313 (1985), pp. 1322-1326
[37.]
L.H. Silveira, C.L. Hubble, L.J. Jara, et al.
Prevention of anticardiolipin antibody-related pregnancy losses with prednisone and aspirin.
Am J Med, 93 (1992), pp. 403-411
[38.]
G. Ruiz-Irastorza, M.J. Cuadrado, M.A. Khamashta.
Enfermedades autoinmunes sistémicas durante el embarazo: una aproximación práctica.
Med Clin (Barc), 111 (1998), pp. 785-797
[39.]
R.K. Silver, S.N. MacGregor, J.S. Sholl, et al.
Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients.
Am J Obstet Gynecol, 169 (1993), pp. 1411-1417
[40.]
F.S. Cowchock, E.A. Reece, D. Balaban, et al.
Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with lowdose heparin.
Am J Obstet Gynecol, 166 (1992), pp. 1318-1323
[41.]
G. Ruiz-Irastorza, M.A. Khamashta, G.R.V. Hughes.
Treatment of pregnancy loss in Hughes’ syndrome: a critical update.
Autoimmun Rev, 1 (2002), pp. 298-304
[42.]
G. Ruiz-Irastorza, M.A. Khamashta, G.R.V. Hughes.
Antiaggregant and anticoagulant therapy in systemic lupus erythematosus and Hughes’ syndrome.
Lupus, 10 (2001), pp. 241-245
[43.]
S. Bates, I.A. Greer, J. Hirsh, et al.
Use of antithrombotic agents during pregnancy. The seventh ACCP conference on antithrombotic and thrombolytic therapy.
Chest, 126 (2004), pp. S627-S644
[44.]
R. Pauzner, M. Dulitzki, P. Lanevitz, et al.
Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy.
Thromb Haemost, 86 (2001), pp. 1379-1384
[45.]
G. Ruiz-Irastorza, M.A. Khamashta, G.R. Hughes.
Systemic lupus erythematosus and antiphospholipid syndrome during pregnancy: maternal and fetal complications and their management.
Isr Med Assoc J, 2 (2000), pp. 462-469
[46.]
G. Ruiz-Irastorza, M.A. Khamashta.
Management of thrombosis in antiphospholipid syndrome and systemic lupus erythematosus in pregnancy.
Ann N Y Acad Sci, 1051 (2005), pp. 606-612
[47.]
C. Patrono, B. Coller, J.E. Dalen, et al.
Platelet-active drugs: the relationships among dose, effectiveness and side-effects.
Chest, 114 (1998), pp. S470-S488
[48.]
J.I. Weitz.
Low-molecular-weight heparins.
N Engl J Med, 337 (1997), pp. 688-698
[49.]
D. Fitzmaurice, F.D. Hobbs.
Thromboembolism.
Clinical Evidence, 3 (2000), pp. 135-142
[50.]
M. Natajaran.
Unstable angina.
Clinical Evidence, 3 (2000), pp. 143-154
[51.]
A. Tincani, W. Branch, R.A. Levy, et al.
Treatment of pregnant patients with antiphospholipid syndrome.
Lupus, 12 (2003), pp. 524-529
[52.]
R. Rai, H. Cohen, M. Dave, et al.
Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies).
BMJ, 314 (1997), pp. 253-257
[53.]
R.G. Farquharson, S. Quenby, M. Greaves.
Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment.
Obstet Gynecol, 100 (2002), pp. 408-413
[54.]
W.H. Kutteh.
Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone.
Am J Obstet Gynecol, 174 (1996), pp. 1584-1589
[55.]
F. Carmona, J. Font, M. Azulay, et al.
Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: a multivariate analysis.
Am J Reprod Immunol, 46 (2001), pp. 274-279
[56.]
R. Kaaja, H. Julkunen, P. Ämmälä, et al.
Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies.
Acta Obstet Gynecol Scand, 72 (1993), pp. 63-66
[57.]
J. Arnout, B. Spitz, C. Wittevrongel, et al.
High-dose intravenous immunoglobulin treatment of a pregnant patient with an antiphospholipid syndrome: immunological changes associated with a successful outcome.
Thromb Haemost, 71 (1994), pp. 741-747
[58.]
J.A. Spinnato, A.L. Clark, S.S. Pierangeli, et al.
Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy.
Am J Obstet Gynecol, 172 (1995), pp. 690-694
[59.]
D.W. Branch, A.M. Peaceman, M. Druzin, et al.
A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy.
Am J Obstet Gynecol, 182 (2000), pp. 122-127
[60.]
G. Triolo, A. Ferrante, F. Ciccia, et al.
Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the tratment of recurrent fetal loss associated with antiphospholipid antibodies.
Arthritis Rheum, 48 (2003), pp. 728-731
[61.]
A.T. Papageorghiou, N. Roberts.
Uterine artery Doppler screening for adverse pregnancy outcome.
Curr Opin Obstet Gynecol, 17 (2005), pp. 584-590
[62.]
A. Caruso, S. De Carolis, S. Ferrazzani, et al.
Pregnancy outcome in relation to uterine artery flow velocity waveforms and clinical characteristics in women with antiphospholipid syndrome.
Obstet Gynecol, 82 (1993), pp. 970-977
[63.]
E. Guzman, H. Schulman, L. Bracero, et al.
Uterine-umbilical artery doppler velocimetry in pregnant women with systemic lupus erythematosus.
J Ultrasound Med, 11 (1992), pp. 275-281
[64.]
S. Kerslake, K.E. Morton, E. Versi, et al.
Early doppler studies in lupus pregnancy.
Am J Reprod Immunol, 28 (1992), pp. 172-175
[65.]
J.S. Levine, D.W. Branch, J. Rauch.
The antiphospholipid syndrome.
N Engl J Med, 346 (2002), pp. 752-763
[66.]
M.A. Khamashta, M.J. Cuadrado, F. Mujic, et al.
The management of thrombosis in the antiphospholipid-antibody syndrome.
N Engl J Med, 332 (1995), pp. 993-997
[67.]
M.H. Rosove, P.M.C. Brewer.
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.
Ann Intern Med, 117 (1992), pp. 303-308
[68.]
S. Schulman, E. Svenungsson, S. Granqvist, And the Duration of Anticoagulation Study Group.
Anticardiolipin antibodies predict early recurrence in thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy.
Am J Med, 104 (1998), pp. 332-338
[69.]
C. Kearon, M. Gent, J. Hirsh, et al.
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
N Engl J Med, 340 (1999), pp. 901-907
[70.]
R.G. Wetzl.
Anestesiological aspects of pregnancy in patients with rheumatic diseases.
Lupus, 13 (2004), pp. 699-702
[71.]
B.J. Hunt, M.A. Khamashta, L. Lakasing, et al.
Thromboprophylaxis in antiphospholipid syndrome pregnancies with previous cerebral arterial thrombotic events: is warfarin preferable?.
Thromb Haemost, 79 (1998), pp. 1060-1061
[72.]
N.S. Pattison, L.W. Chamley, M. Birdsall, et al.
Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial.
Am J Obstet Gynecol, 183 (2000), pp. 1008-1012
[73.]
B.J. Sanson, A.W.A. Lensing, M.H. Prins, et al.
Safety of low-molecular-weight heparin in pregnancy: a systematic review.
Thromb Haemost, 81 (1999), pp. 668-672
[74.]
C. Nelson-Piercy, E. Letsky, M. De Swiet.
Low-molecularweight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk.
Am J Obstet Gynecol, 176 (1997), pp. 1062-1068
[75.]
B.J. Hunt, H.A. Doughty, G. Majumdar, et al.
Thromboprophylaxis with low molecular weight heparin (fragmin) in high risk pregnancies.
Thromb Haemost, 77 (1997), pp. 39-43
[76.]
M. Bazaan, V. Donvito.
Low-molecular-weight heparin during pregnancy.
Thromb Res, 101 (2001), pp. V175-V186
[77.]
British Committee for Standards in Haematology.
Guidelines on oral anticoagulation: third edition.
Br J Haematol, 101 (1998), pp. 374-387
[78.]
G. Ruiz-Irastorza, M.A. Khamashta, C. Nelson-Piercy, et al.
Lupus pregnancy: is heparin a risk factor for osteoporosis?.
Lupus, 10 (2001), pp. 597-600
[79.]
G. Ruiz-Irastorza, M.A. Khamashta, G.RV. Hughes.
Heparin and osteoporosis during pregnancy: 2002 update.
Lupus, 11 (2002), pp. 680-682
[80.]
S. Schulman, M. Hellgren-Wangdahl.
Pregnancy, heparin and osteoporosis.
Thromb Haemost, 87 (2002), pp. 180-181
[81.]
M. Monreal, E. Lafoz, A. Olive, et al.
Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin®) in patients with venous thromboembolism and contraindications to coumarin.
Thromb Haemost, 71 (1994), pp. 7-11
[82.]
M. Monreal, F.J. Roncales, J. Ruiz, et al.
Secondary prevention of venous thromboembolism: a role for low-molecularweight heparin.
Haemostasis, 28 (1998), pp. 236-243
[83.]
T.C. Dahlman.
Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin.
Am J Obstet Gynecol, 168 (1993), pp. 1265-1270
[84.]
J. Shefras, R.G. Farquharson.
Bone density studies in pregnant women receiving heparin.
Eur J Obstet Gynecol Reprod Biol, 65 (1996), pp. 171-174
[85.]
V. Pettilä, P. Leinonen, A. Markkola, et al.
Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin.
Thromb Haemost, 87 (2002), pp. 182-186
Copyright © 2006. Sociedad Española de Reumatología
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.